Increased Serum Concentration of Soluble CD30 in Patients with Graves' Disease and Hashimoto's Thyroiditis

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 6, 1997, Pages 1757-1760

  Okumura, Motoshi ^a   Hidaka, Yoh ^a   Kuroda, Shoko ^a   Takeoka, Keiko ^a   Tada, Hisato ^a   Amino, Nobuyuki ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CD30 ANTIGEN;

ADULT; ARTICLE; AUTOIMMUNE THYROIDITIS; FEMALE; GRAVES DISEASE; HUMAN; IMMUNOLOGY; MIDDLE AGED; REFERENCE VALUE; SOLUBILITY; THYROTOXICOSIS;

ADULT; ANTIGENS, CD30; AUTOANTIBODIES; FEMALE; GRAVES DISEASE; HUMANS; MIDDLE AGED; REFERENCE VALUES; SOLUBILITY; THYROIDITIS, AUTOIMMUNE; THYROTOXICOSIS;

EID: 0031156842     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.6.1757     Document Type: Article

References (23)

1. Mosmann TR, Sad S. 1996 The expanding universe of T-cell subsets: Th1. Th2 and more. Immunol Today. 17:138-146.
2. Burman KD, Baker JJ. 1985 Immune mechanisms in Graves' disease. Endocr Rev. 6:183-232.
3. Chiovato L, Bassi P, Santini F, et al. 1993 Antibodies producing complement-mediated thyroid cytotoxicity in patients with atrophic or goitrous autoimmune thyroiditis. J Clin Endocrinol Metab. 77:1700-1705.
4. Bognet U, Schleusener H, Wall JR. 1984 Antibody-dependent cell mediated cytotoxicity against human thyroid cells in Hashimoto's thyroiditis but not Graves' disease. J Clin Endocrinol Metab. 59:734-738.
5. MacKenzie WA, Schwartz AE, Friedman EW, Davies TF. 1987 Intrathyroidal T cell clones from patients with autoimmune thyroid disease. J Clin Endocrinol Metab. 64:818-824.
6. Iwatani Y, Hidaka Y, Matsuzuka F, Kuma K, Amino N. 1993 Intrathyroidal lymphocyte subsets, including unusual CD4+ CD8+ cells and CP3loTCR alpha beta lo/-CD4-CD8- cells, in autoimmune thyroid disease. Clin Exp Immunol. 93:430-436.
7. Durkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H. 1992 Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell. 68:421-427.
8. Del Prete G, De Carli M, Almerigogna F, et al. 1995 Preferential expression of CD30 by human CD4+ T cells producing Th2-tvpe cytokines. FASEB J. 9:81-86.
9. Falini B, Pileri S, Pizzolo G, et al. 1993 CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 85:1-14.
10. Pizzolo G, Vinante F, Morosato L, et al. 1994 High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS. AIDS. 8:741-745.
11. Tamaki H, Amino N, Aozasa M, Mori M, Tanizawa O, Miyai K. 1987 Serial changes in thyroid-stimulating antibody and thyrotropin binding inhibitor immunoglobulin at the time of postpartum occurrence of thyrotoxicosis in Graves' disease. J Clin Endocrinol Metab. 65:324-330.
12. Schwab U, Stein H, Gerdes J, et al. 1982 Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature. 299:65-67.
13. Nawrocki JF, Kirsten ES, Fisher RI. 1988 Biochemical and structural properties of a Hodgkin's disease-related membrane protein. J Immunol. 141:672-680.
14. Josimovic-Alasevic O, Durkop H, Schwarting R, Backe E, Stein H, Diamantstein T. 1989 Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur J Immunol. 19:157-162.
15. Nadali G, Vinante F, Ambrosetti A, et al. 1994 Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. J Clin Oncol. 12:793-797.
16. Gerli R, Muscat C, Bistoni O, et al. 1995 High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints. Clin Exp Immunol. 102:547-550.
17. Caligaris-Cappio F, Bertero MT, Converso M, et al. 1995 Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Clin Exp Rheumatol. 13:339-343.
18. Mullins RJ, Cohen SB, Webb LM, et al. 1995 Identification of thyroid stimulating hormone receptor-specific T cells in Graves' disease thyroid using autoantigen-transfected Epstein-Barr virus-transformed B cell lines. J Clin Invest. 96:30-37.
19. Heuer M, Aust G, Ode-hakim S, Scherbaum WA. 1996 Different cytokine mRNA profiles in Graves' disease, Hashimoto's thyroiditis, and nonautoimmune thyroid disorders determined bu quantitative reverse transcriptase polymerase chain reaction (RT-PCR). Thyroid. 6:97-106.
20. Hidaka Y, Amino N, Iwatani Y, Itoh E, Matsunaga M, Tamaki H. 1993 Recurrence of thyrotoxicosis after attack of allergic rhinitis in patients with Graves' disease. J Clin Endocrinol Metab. 77:1667-1670.
21. Hidaka Y, Masai T, Sumizaki H, Takeoka K, Tada H, Amino N. 1996 Onset of Graves' thyrotoxicosis after an attack of allergic rhinitis. Thyroid. 6:347-351.
22. Del Prete G, De Carli M, D'Elios MM, et al. 1995 CD30-mediated signaling promotes the development of human T helper type 2-like T cells. J Exp Med. 182:1655-1661.
23. Smith CA, Gruss HJ, Davis T, et al. 1993 CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell. 73:1349-1360.